Heart muscle dysfunction in adolescents may soon have its first targeted molecular therapy, potentially transforming treatment for a condition that currently relies on invasive procedures or lifelong activity restrictions. The cardiac myosin inhibitor mavacamten, already proven effective in adults with obstructive hypertrophic cardiomyopathy, is now advancing into pediatric testing through the SCOUT-HCM trial.
This phase 3 study will enroll symptomatic adolescents aged 12-17 with obstructive hypertrophic cardiomyopathy, randomizing them to receive either mavacamten or placebo for 28 weeks. The drug works by directly inhibiting cardiac myosin, reducing the excessive muscle contractions that create dangerous outflow obstructions in the left ventricle. Participants begin with either 2.5mg or 5mg daily doses, with adjustments based on echocardiographic measurements of left ventricular outflow tract gradients and ejection fraction.
Hypertrophic cardiomyopathy affects roughly 1 in 500 people and represents the leading cause of sudden cardiac death in young athletes. Current pediatric management relies heavily on beta-blockers, calcium channel blockers, or surgical interventions like septal myectomy. Mavacamten's mechanism offers a fundamentally different approach by targeting the molecular basis of the disease rather than just managing symptoms. The adult data showing improved cardiac function and exercise capacity suggest meaningful potential for adolescent patients who face decades of disease progression. However, this remains the first controlled study in pediatric populations, and questions about long-term developmental effects and optimal dosing strategies in growing hearts will require careful monitoring throughout the planned 144-week extension period.